Keywords: vegf, trap, maintains, gain, visual, acuity, germany
VEGF Trap maintains gain in visual acuity
Article | 12 May 2008
Germany's Bayer HealthCare AG and USA-based Regeneron Pharmaceuticals say that their VEGF Trap-Eye dosed on an as-needed dosing schedule maintained ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
